Topics
Innovation
Laser
Medical
Practice
Research
Surgical
Training
The next act in medical glaucoma management.
View Issue
Sponsored by Aerie Pharmaceuticals
View Insert
Editorially independent content supported with advertising from Novartis
Sponsored by Glaucoma Research Foundation
Editorially Independent Content Supported With Advertising by Zeiss and Alcon a Novartis Division
Sponsored by Santen
In This Issue
Steven D. Vold, MD
Nisha Chadha, MD, and Timothy P. Fox, MD
Antivascular endothelial growth factor agents have dramatically changed the early management of neovascular glaucoma.
Mark Slabaugh, MD, and Matthew Ohr, MD
Patchless glaucoma tube shunts can result in great outcomes—for the right patients.
Constance O. Okeke, MD, MSCE
An exploration of progress and challenges in the field.
Lisa Brothers Arbisser, MD; Rosa Braga-Mele, MD, MEd, FRCSC; Kendall E. Donaldson, MD, MS; Soosan Jacob, MD, MS, FRCS, DNB; Jennifer Loh, MD; Cynthia Matossian, MD; Marguerite McDonald, MD; Constance O. Okeke, MD, MSCE; Mildred M. G. Olivier, MD; Heather Ready, MBA; and Sarwat Salim, MD
Elizabeth Marlow, MD
An overview of devices in development.
Inder Paul Singh, MD
Could an external drug delivery device help knock out noncompliance?
Brian Flowers, MD
Enhancing adherence to glaucoma therapy with punctal plug drug delivery platforms.
Malik Y. Kahook, MD; Jeffrey R. SooHoo, MD; and Leonard K. Seibold, MD
Rho kinase inhibitors could shake up glaucoma medical therapy.
Janet B. Serle, MD
Latanoprostene bunod shows promise.
Carla J. Siegfried, MD
Could this therapeutic strategy solve some problems?
Lauren Seo and Nathan Radcliffe, MD
Treating ocular surface disease in glaucoma patients.
Francis W. Price Jr, MD
The top five of five.
Reay H. Brown, MD; Leon W. Herndon, MD; Mildred M. G. Olivier, MD; Oluwatosin U. Smith, MD; and Michael C. Stiles, MD
Subscribe
Stay up to date all on all things Glaucoma by signing up to receive our print publication or subscribe to our email alerts.